The US Trump administration has announced new pricing outcomes for 15 medicines funded by major government programs, securing what officials describe as an average net reduction of 44 per cent, equivalent to US$12 billion, compared to what the programs paid for the treatments in 2024.
US secures significant price reductions on 15 medicines in second round of medicare negotiations
November 26, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Dispatched' Podcast - Special episode
June 5, 2026 - - Podcast -
Opthea returns to ASX and works to restart eye therapy candidate
June 5, 2026 - - Latest News -
A clear disconnect between the public and private on 'Most Favored Nation' pricing
June 5, 2026 - - Latest News -
New blueprint charts a potential policy path forward on biosimilars
June 4, 2026 - - Latest News -
Study confirms pharmacist led care expands timely access to urinary tract infection treatment and contraception
June 4, 2026 - - BioPharma -
Officials talk down the prospect of MFN impact on the PBS
June 4, 2026 - - Latest News -
Novo Nordisk's Marie Krogh Prize returns and crosses the Tasman to back early career women in science
June 4, 2026 - - Latest News

